Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Hanchett

Dentist, Oral and Maxillofacial Pathology Phoenix, AZ Doctor of Dentistry

NPI 1356570824 CMS profile 1396836

5121 E Pasadena Ave, Phoenix, AZ 85018

Open in the dashboard

General payments

$4,003

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Hanchett of Phoenix, AZ is reported in the CMS Open Payments database as having received $4,003 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Dentist, Oral and Maxillofacial Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $790 10
2024 General $526 8
2023 General $330 11
2022 General $197 5
2021 General $1,187 6
2020 General $815 8
2019 General $159 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Hanchett
  • Dentist, Oral and Maxillofacial Pathology median
  • Middle half of Dentist, Oral and Maxillofacial Pathology
  • National median

In program year 2025, general payments to Matthew Hanchett were reported at $790. Among 128 Dentist, Oral and Maxillofacial Pathology profiles paid that year, the median was $91 and the middle half received between $35 and $330.

Show as a table
Year Matthew Hanchett Dentist, Oral and Maxillofacial Pathology median Middle half National median
2019 $159 $106 $28–$326 $163
2020 $815 $109 $33–$500 $114
2021 $1,187 $104 $30–$557 $132
2022 $197 $104 $37–$432 $149
2023 $330 $152 $41–$372 $160
2024 $526 $100 $38–$354 $164
2025 $790 $91 $35–$330 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Straumann USA LLC $2,091 17 payments
  2. Acumed LLC $993 16 payments
  3. Stryker Corporation $630 6 payments
  4. Osteomed LLC $64 3 payments
  5. Dentsply Sirona Inc $63 2 payments
  6. DENTSPLY IH Inc. $50 1 payment
  7. Nobel Biocare USA $43 2 payments
  8. BioHorizons Implant Systems Inc. $38 2 payments
  9. Zimmer Biomet Holdings, Inc. $15 1 payment
  10. DePuy Synthes Sales Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,333 42 payments
  2. Gift $1,005 4 payments
  3. Travel and Lodging $462 2 payments
  4. Education $200 2 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3 1 payment
Products named General payments · program years 2019–2025
  1. OsteoMed Craniomaxillofacial $748 10 payments
  2. OsteoMed Craniomaxillofacial $281 5 payments
  3. VSP SYSTEM, VSP CRANIAL $239 2 payments
  4. NA Craniomaxillofacial $156 1 payment
  5. NA Craniomaxillofacial $132 1 payment
  6. AccuPlate Patient-Specific Plate $112 3 payments
  7. NA Craniomaxillofacial $96 1 payment
  8. SMARTLOCK $92 1 payment
  9. OsteoMed Craniomaxillofacial $74 2 payments
  10. CUSTOM IMPLANTS $71 1 payment
  11. Other $385 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

489

Median for Maxillofacial Surgery: 343

Drug cost

$1,906

Median for Maxillofacial Surgery: $1,437

Branded share of claims

27.8%

Median for Maxillofacial Surgery: 21.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibuprofen Generic 114 $503
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 121 $485
Chlorhexidine Gluconate Generic 104 $396
Amoxicillin Generic 88 $235
Clindamycin Hcl Generic 23 $159
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 15 $105
Alprazolam Generic 24 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 692 Part D prescribers listed as Maxillofacial Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$1,819

Medicare's payments for the services billed

Medicare patients

12

Average age 76

Services billed

21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dentist, Oral and Maxillofacial Pathology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record